The DOI matches its Crossref record; the references it cites are not checked yet.
Perinatal Outcomes in Pregnancies Managed with Antenatal Insulin Glargine
Abstract
We compared perinatal outcomes in pregnancies in which insulin glargine was used in the management of patients with pregnancies in which standard insulin therapy was used at a single institution. A retrospective analysis of 114 pregnant patients with diabetes (pregestational or gestational) managed at a single center between January 2004 and August 2006 was undertaken. Sixty-five patients managed with insulin glargine were compared with 49 patients managed with neutral protamine Hagedorn (NPH) insulin. Both groups were also treated with short-acting insulin (either regular, lispro, or aspart insulin). Maternal age, parity, prepregnancy weight, body mass index, duration of diabetes, hemoglobin A (1C) (at entry and final recorded) and gestational age at entry were similar for each group (glargine and NPH). Thirty patients had gestational diabetes (18 glargine and 12 NPH); there were no differences in numbers of patients in higher-order White's classification between the two groups. Cesarean section for obstetric reasons included labor abnormalities, malpresentation, fetal distress, and suspected macrosomia. There were no differences in gestational age at delivery, birth weight, preeclampsia, or frequency of cesarean section (total or for obstetric reasons). The frequency of shoulder dystocia was higher in the NPH group. Regarding neonatal outcomes, gestational age at delivery, birth weight, Apgar scores, admission to the neonatal intensive care unit, respiratory distress syndrome, hypoglycemia, and congenital anomalies were similar between the two groups. From this retrospective analysis, no adverse maternal or neonatal effects were seen from maternal administration of insulin glargine. A larger multicenter study is needed to confirm these findings. This preliminary report suggests that use of insulin glargine during pregnancy can be considered if maternal metabolic control is suboptimal using the standard split-mix regimen.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several retrospective cohort and case-control studies of pregnant women found that overall, the outcome with insulin glargine treatment was no different from, or was superior to, NPH insulin (35, 145–149).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [148]
Citations
The citation lists are queued
They are fetched later and appear here then.
Cited by 35
Metadata
- Authors
- Egerman, R., Ramsey, R., Kao, L., Bringman, J., Haerian, H., Kao, J., & Bush, A.
- Affiliations
- West Virginia University (US)
- University of Tennessee Health Science Center (US)
- ORCID
- Egerman, Robert
- Venue
- American Journal of Perinatology
- Publisher
- Georg Thieme Verlag KG
- Published
- 2009-04-15
- Volume
- 26
- Issue
- 08
- Pages
- 591-595
- ISSN
- 0735-1631 (ISSN-L)
- 1098-8785
- OpenAlex
- W2051504119
- Cited by
- 35
- References
- 0
- Citations by year
- 2022: 1 · 2021: 2 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 4 · 2014: 1 · 2013: 3 · 2012: 3
- FWCI
- 5.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Perinatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulin glargine, perinatal outcomes, gestational diabetes mellitus, pregestational diabetes, NPH insulin, cesarean section, shoulder dystocia, neonatal outcomes, maternal glycemic control, congenital malformations
- MeSH terms
- Insulin Glargine, Adult, Female, Humans, Hypoglycemic Agents, Infant, Newborn, Insulin, Insulin, Isophane, Pregnancy, Pregnancy in Diabetics, Pregnancy Outcome, Diabetes, Gestational, Insulin, Long-Acting, Insulin Aspart, Insulin Lispro
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Perinatal Outcomes in Pregnancies Managed with Antenatal Insulin Glargine. https://app.cochat.ai/papers/10.1055/s-0029-1220782
- The paper
- Egerman, R., Ramsey, R., Kao, L., Bringman, J., Haerian, H., Kao, J., & Bush, A. (2009). Perinatal Outcomes in Pregnancies Managed with Antenatal Insulin Glargine. American Journal of Perinatology. https://doi.org/10.1055/s-0029-1220782
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.